Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 605
Filter
Add more filters

Publication year range
1.
Clin Exp Dermatol ; 47(4): 724-729, 2022 Apr.
Article in English | MEDLINE | ID: mdl-34826148

ABSTRACT

BACKGROUND: Recent evidence has suggested that oral antihistamines could have a beneficial role in atopic dermatitis (AD) because of their anti-inflammatory action. AIM: To evaluate the effectiveness of adding an oral second-generation, nonsedating, H1-receptor antihistamine (fexofenadine) to topical treatment in AD. METHODS: In this prospective randomized study, 50 patients with a diagnosis of mild to moderate AD were recruited and randomized into two groups: Group A was given appropriate topical treatment (topical tacrolimus 0.03-0.1% ointment once daily along with topical fluticasone propionate 0.05% cream once daily, as well as paraffin-based emollients) combined with oral fexofenadine, while Group B was given appropriate topical treatment only. Both groups received the respective treatments for 8 weeks. RESULTS: There was no significant difference between the two groups in terms of the SCORing Atopic Dermatitis and the 5-dimensions Itch Scale at any of the time points (Weeks 2, 4 and 8). However, in the fexofenadine group, the level of serum interleukin (IL)-31 decreased significantly from baseline to Week 8 of treatment. CONCLUSIONS: Although we could not conclusively confirm the clinical efficacy of adding oral fexofenadine to topical treatment in AD, serological evaluation indicates that fexofenadine treatment can lead to significant lowering of serum IL-31 levels in patients with AD.


Subject(s)
Dermatitis, Atopic , Administration, Topical , Child , Dermatitis, Atopic/drug therapy , Double-Blind Method , Humans , Interleukins , Prospective Studies , Tacrolimus/therapeutic use , Terfenadine/analogs & derivatives , Terfenadine/therapeutic use , Treatment Outcome
2.
Clin Exp Dermatol ; 46(4): 795-799, 2021 Jun.
Article in English | MEDLINE | ID: mdl-33625737

ABSTRACT

A 5-year-old boy presented with generalized cutaneous erosions, severe scarring, depigmentation and contractures affecting major joints. The lesions had initially affected his ears, nose, feet, and the genital and ocular mucosa, leading to significant depigmentation, scarring, contractures and mutilation. The whole of the trunk and limbs were involved at the time of presentation, with the exception of some islands of spared skin on the proximal thighs, legs, nipples and external genitalia. Electron microscopy revealed a split in the sublamina densa with the absence of anchoring fibrils, suggestive of dystrophic epidermolysis bullosa (EB). Immunofluorescence antigen mapping demonstrated a broad reticulate pattern of staining with collagen IV, VII, and laminin 332 in the floor of the blister, suggestive of Kindler syndrome. Next-generation sequencing revealed a de novo heterozygous missense mutation (a variant of unknown significance) in exon 22 of the phospholipase-C gamma 2 gene (PLCG2), which resulted in a substitution of serine by asparagine at codon 798 (p.Asp798Ser), a result that was validated using Sanger sequencing. The child was diagnosed with PLCG2-associated antibody deficiency and immune dysregulation (PLAID)/autoinflammation and PLCG2-associated antibody deficiency and immune dysregulation (APLAID) syndrome. The cutaneous and corneal erosions, inflammation and scarring of this magnitude, and the eventual result of death have not been described previously for the PLAID/APLAID spectrum previously. In conclusion, this was an unusual acquired autoinflammatory severe EB-like disease that may be associated with de novo PLCG2 mutation.


Subject(s)
Epidermolysis Bullosa/genetics , Mutation, Missense , Phospholipase C gamma/genetics , Blister/genetics , Child, Preschool , High-Throughput Nucleotide Sequencing , Humans , Male , Microscopy, Electron , Periodontal Diseases/genetics , Phenotype , Photosensitivity Disorders/genetics , Skin/pathology
3.
Clin Exp Dermatol ; 45(6): 679-684, 2020 Aug.
Article in English | MEDLINE | ID: mdl-32449205

ABSTRACT

Paediatric morphoea is a debilitating fibrosing disorder of uncertain aetiology, affecting the skin and subcutaneous tissues. Defining optimum management strategies in paediatric morphoea remains an ongoing challenge, owing to the varied presentations and a relative paucity of paediatric-specific studies. We performed a literature search on PubMed, MEDLINE and Google Scholar, using keywords such as 'pediatric morphea', 'juvenile localised scleroderma' and 'juvenile systemic sclerosis'. Relevant studies, including randomized trials, reviews of standard current guidelines and original research articles, were selected and results analysed before summarizing them. In Part 1 of this review, we described the epidemiology, aetiopathogenesis and clinical classification; in this part, we discuss the diagnosis, markers of disease activity, management and natural history in paediatric morphoea.


Subject(s)
Adrenal Cortex Hormones/therapeutic use , Phototherapy , Scleroderma, Localized/diagnosis , Scleroderma, Localized/therapy , Biomarkers , Child , Humans , Methotrexate/therapeutic use , Mycophenolic Acid/therapeutic use , Scleroderma, Localized/pathology , Scleroderma, Systemic/diagnosis , Scleroderma, Systemic/therapy
4.
Clin Exp Dermatol ; 45(6): 673-678, 2020 Aug.
Article in English | MEDLINE | ID: mdl-32472964

ABSTRACT

Morphoea, also known as localized scleroderma, is a debilitating fibrosing disorder of uncertain aetiology, affecting the skin and subcutaneous tissues. Paediatric-onset disease is not uncommon and is associated with frequent relapses. The disease has complex pathogenetic mechanisms and multiple clinical subtypes, and affects children of all ages. Recent research has focused on elucidating the disease pathophysiology and identifying measures of disease activity. We performed a literature search on PubMed, MEDLINE and Google Scholar, using keywords such as 'pediatric morphea', 'juvenile localised scleroderma' and 'juvenile systemic sclerosis'. Relevant studies, including randomized trials, reviews of standard current guidelines and original research articles, were selected, and results were analysed before being summarized. In the first of this two-part review, we provide a bird's-eye view of the current literature concerning the epidemiology, aetiopathogenesis and clinical classification of paediatric morphoea; in Part 2, we review the diagnosis, markers of disease activity, management and natural history.


Subject(s)
Scleroderma, Localized , Child , Humans , Scleroderma, Localized/classification , Scleroderma, Localized/epidemiology , Scleroderma, Localized/etiology , Scleroderma, Systemic/classification , Scleroderma, Systemic/epidemiology , Scleroderma, Systemic/etiology
5.
J Eur Acad Dermatol Venereol ; 33(7): 1349-1357, 2019 Jul.
Article in English | MEDLINE | ID: mdl-30883932

ABSTRACT

BACKGROUND: Acquired dermal macular hyperpigmentation (ADMH) is an umbrella term including lichen planus pigmentosus, erythema dyschromicum perstans and pigmented contact/cosmetic dermatitis. OBJECTIVE: To establish contact sensitization to hair colours as an aetiological factor for ADMH. METHODS: Detailed clinical examination, skin biopsies, and patch and photo-patch testing with Indian standard series and patient's own cosmetic products were performed. RESULTS: Thirty-nine (36.1%) patients were found to demonstrate a positive patch/photo-patch test with 35/39 reacting to their own products (all were hair colours) and 16/39 reacting to antigens from commercial series (commonly paraphenylenediamine). Fourteen patients developed delayed hyperpigmentation on positive patch-test sites at 1 month. Higher mean age, symptomatic pigmentation (pruritus, burning and photosensitivity), hair margins involvement (outer surface, helix and lobule of ear; temples and preauricular area), ill-defined lesions, epidermal atrophy and epidermal melanization extending >3 layers were significantly common in patch-test-positive patients. Well-defined lesions, perioral involvement and associated lichen planus were clinical pointers towards patch-test negativity. CONCLUSION: Index study exemplifies that patch-test results have distinct clinical and histopathological correlates in ADMH. Hair dye contact sensitization appears to be an important aetiological factor in about one-third patients presenting with ADMH.


Subject(s)
Dermatitis, Contact/etiology , Dermatitis, Perioral/chemically induced , Hair Dyes/adverse effects , Hyperpigmentation/chemically induced , Adolescent , Adult , Aged , Dermatitis, Contact/pathology , Female , Humans , Hyperpigmentation/pathology , Male , Middle Aged , Neck , Patch Tests , Prospective Studies , Pruritus/chemically induced , Young Adult
6.
Dermatol Ther ; 31(1)2018 Jan.
Article in English | MEDLINE | ID: mdl-29124831

ABSTRACT

Topical corticosteroids are considered to be the most effective treatment for oral lichen planus (OLP). Methotrexate has been found to be effective in extensive cutaneous lichen planus. The objectives of the study were to evaluate the clinical efficacy and safety of topical triamcinolone 0.1% oral paste, oral methotrexate and a combination of these in symptomatic moderate-to- severe OLP. Forty-five patients were recruited and were allocated to three treatment arms with 15 patients in each treatment arm. They were treated for a period of 16 weeks or until complete clinical remission, whichever was earlier. The parameters assessed were clinical severity score, visual analogue score, and quality of life impairment questionnaire score. Forty-three patients completed the study. All three treatment modalities were effective. The patients in the combination group had significantly better reduction in the outcome parameters assessed compared to the other two groups. Nine patients achieved complete clinical remission, 6 in the combination group and 3 in the topical triamcinolone group. Systemic methotrexate, alone or in combination with topical triamcinolone, is effective in management of moderate to severe OLP.


Subject(s)
Glucocorticoids/administration & dosage , Immunosuppressive Agents/administration & dosage , Lichen Planus, Oral/drug therapy , Methotrexate/administration & dosage , Triamcinolone Acetonide/administration & dosage , Administration, Oral , Administration, Topical , Adult , Drug Therapy, Combination , Female , Glucocorticoids/adverse effects , Humans , Immunosuppressive Agents/adverse effects , Lichen Planus, Oral/diagnosis , Male , Methotrexate/adverse effects , Middle Aged , Ointments , Prospective Studies , Quality of Life , Recurrence , Remission Induction , Severity of Illness Index , Surveys and Questionnaires , Time Factors , Treatment Outcome , Triamcinolone Acetonide/adverse effects
7.
Clin Exp Dermatol ; 43(1): 36-41, 2018 Jan.
Article in English | MEDLINE | ID: mdl-28940653

ABSTRACT

BACKGROUND: Melasma is relatively uncommon in males, and there is a paucity of data on male melasma, including its clinical pattern, triggering factors, endocrine profile and histopathological findings. AIM: To characterize the clinical findings and aetiological factors, including hormonal and histopathological features, of male melasma. METHODS: Male patients with melasma and age- and sex-matched healthy controls (HCs) were recruited. Demographic profile, risk factors, clinical pattern and Wood lamp findings of patients were recorded. Sera were obtained from patients and HCs to determine hormone levels. Biopsy specimens were obtained from lesional and adjacent nonlesional skin. RESULTS: In total, 50 male patients with melasma and 20 HCs were recruited into the study. Mean age of patients was 27.58 ± 4.51 years. The most common clinical pattern of melasma was malar, which occurred in 52% of cases. Positive family history was present in 16% of patients, while 34% had disease aggravation with sun exposure and 62% used mustard oil for hair growth and/or as an emollient. Wood lamp examination revealed epidermal-type melasma in 54% of patients. There were no significant differences in hormone levels between patients and HCs. Histologically, epidermal melanin, elastotic degeneration, vascular proliferation and mast cells were more pronounced in lesional compared with nonlesional skin. Absent to weak expression of oestrogen receptors, progesterone receptors and stem cell factor was observed in lesional skin. CONCLUSION: Ultraviolet light and mustard oil are important causative factors in male melasma. Although stress and family history may contribute, hormonal factors possibly have no role. Quantitative analysis of immunohistochemical markers would provide insight in understanding the pathogenesis of melasma.


Subject(s)
Hormones/blood , Melanosis/etiology , Mustard Plant/adverse effects , Plant Oils/adverse effects , Skin/pathology , Ultraviolet Rays/adverse effects , Adult , Case-Control Studies , Genetic Predisposition to Disease , Humans , Male , Melanosis/blood , Melanosis/genetics , Melanosis/pathology , Risk Factors
8.
Br J Dermatol ; 177(6): 1583-1589, 2017 12.
Article in English | MEDLINE | ID: mdl-28498563

ABSTRACT

BACKGROUND: The oral mucosal lesions of patients with pemphigus vulgaris are known to show more treatment refractoriness than skin lesions. OBJECTIVES: To identify which clinical and laboratory parameters may indicate treatment refractoriness of oral lesions in pemphigus vulgaris. METHODS: This was a prospective study of 50 adults with pemphigus vulgaris and oral lesions; patients were given treatment appropriate for overall disease severity. Treatment refractoriness was defined arbitrarily as less than 75% reduction in oral objective Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) after treatment for 6 months. RESULTS: Of 46 patients who completed the study, 17 (37%) were treatment refractory whereas 29 (63%) were treatment responsive. At baseline, the treatment refractory group had a significantly longer mean duration of disease (P = 0·02) and mean duration of oral lesions (P = 0·01), a higher percentage of lesions in the retromolar trigone (P = 0·05) and on the occlusion line along the buccal mucosa (P = 0·04), a higher percentage of deep/crateriform ulcers (P < 0·001) and erosions with a lichenoid hue (P < 0·001). Herpes simplex virus (HSV) DNA positivity, assessed by polymerase chain reaction in oral tissue scrapings (P = 0·02), was also significantly higher in the treatment refractory group. No other factors we tested for were statistically significant. CONCLUSIONS: Treatment refractoriness of oral lesions was significantly associated with duration of disease/oral lesions; specific morphology and location of oral lesions; and the presence of HSV DNA in the oral cavity. These factors may forewarn the treating physician about a refractory course of oral lesions that may help with counselling patients.


Subject(s)
Dermatologic Agents/therapeutic use , Mouth Diseases/drug therapy , Pemphigus/drug therapy , Adult , Antibodies/metabolism , Azathioprine/therapeutic use , Cyclophosphamide/therapeutic use , DNA, Viral/metabolism , Desmoglein 1/immunology , Desmoglein 3/immunology , Drug Resistance , Drug Therapy, Combination , Female , Humans , Male , Mouth Mucosa/drug effects , Prednisolone/therapeutic use , Prospective Studies , Regression Analysis , Rituximab/therapeutic use , Simplexvirus/genetics , Treatment Outcome
9.
Clin Exp Dermatol ; 42(6): 648-650, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28543318

ABSTRACT

ELISA for anti-desmoglein antibodies (Dsg) is commonly used for diagnosis and assessment of treatment response in pemphigus vulgaris (PV). The present study was conducted to assess the relationship between salivary and serum Dsg1 and Dsg3 levels, and whether salivary Dsg1 and Dsg3 levels correlate with clinical disease severity of oral mucosal lesions in PV. In total 43, patients with PV with predominantly mucosal involvement were recruited. Both serum and salivary samples were collected from the cases, and salivary samples were also collected from five controls. There was a statistically significant correlation between serum and salivary Dsg1 levels and between serum and salivary Dsg3 levels. There was no correlation between serum or salivary Dsg1 and Dsg3 levels with the objective component of the oral mucosal Autoimmune Bullous Skin Disorder Intensity Score (ABSIS). Serum Dsg1 levels significantly correlated with cutaneous ABSIS, but there was no correlation between cutaneous ABSIS and either salivary Dsg1, salivary Dsg3 or serum Dsg3. As salivary Dsg titres correlate with serum levels, saliva can serve as a simple and noninvasive alternative to serum for Dsg ELISA.


Subject(s)
Antibodies/analysis , Desmoglein 1/immunology , Desmoglein 3/immunology , Pemphigus/immunology , Saliva/immunology , Adult , Antibodies/blood , Desmoglein 1/analysis , Desmoglein 3/analysis , Enzyme-Linked Immunosorbent Assay , Female , Humans , Male , Middle Aged , Saliva/chemistry , Severity of Illness Index
13.
Clin Exp Dermatol ; 40(5): 516-20, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25684419

ABSTRACT

Neurofibroma is the most common benign neural tumour. Among the large number of histopathological variants reported, lipomatous neurofibroma is exceedingly infrequent, and shows the presence of intratumoral adipocytes admixed with spindle cells in the dermis. We present a case of a 37-year-old man with lipomatous neurofibromas associated with a giant garment-like pigmented lesion involving his lower trunk and right thigh.


Subject(s)
Lipoma/pathology , Neurofibroma/pathology , Skin Neoplasms/pathology , Adult , Humans , Leg , Male , Torso
SELECTION OF CITATIONS
SEARCH DETAIL